These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 19415993

  • 1. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
    Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, Lupoli G.
    Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
    [Abstract] [Full Text] [Related]

  • 2. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A, FOCUS-D Investigators.
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [Abstract] [Full Text] [Related]

  • 3. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH, Chen JF, Yang BY, Liu RT, Tung SC, Chien WY, Lu YC, Kuo MC, Hsieh CJ, Wang PW.
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 5. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 6. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
    Creatsa M, Pliatsika P, Kaparos G, Antoniou A, Armeni E, Tsakonas E, Panoulis C, Alexandrou A, Dimitraki E, Christodoulakos G, Lambrinoudaki I.
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
    [Abstract] [Full Text] [Related]

  • 7. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 8. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 9. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD, Möller G.
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [Abstract] [Full Text] [Related]

  • 10. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Reverter JL, Holgado S, Alonso N, Salinas I, Granada ML, Sanmartí A.
    Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
    [Abstract] [Full Text] [Related]

  • 11. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD, Farahmand P, Schacht E, Rozehnal A.
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [Abstract] [Full Text] [Related]

  • 12. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis.
    Dagdelen S, Sener D, Bayraktar M.
    Adv Ther; 2007 Mar; 24(6):1314-20. PubMed ID: 18165214
    [Abstract] [Full Text] [Related]

  • 13. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
    Guan YT, Cai LL, Ding HX, Chen GD, Hu Y.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
    [Abstract] [Full Text] [Related]

  • 14. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 15. The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance.
    Pepe J, Petrucci MT, Mascia ML, Piemonte S, Fassino V, Romagnoli E, Minisola S.
    Calcif Tissue Int; 2008 Jun; 82(6):418-26. PubMed ID: 18528609
    [Abstract] [Full Text] [Related]

  • 16. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
    Coin A, Veronese N, Bolzetta F, De Rui M, Manzato E, Sergi G.
    Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
    [Abstract] [Full Text] [Related]

  • 17. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 18. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 19. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators.
    N Engl J Med; 2003 Sep 25; 349(13):1207-15. PubMed ID: 14500804
    [Abstract] [Full Text] [Related]

  • 20. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
    Sajjinanont T, Rajchadara S, Sriassawaamorn N, Panichkul S.
    J Med Assoc Thai; 2005 Nov 25; 88 Suppl 3():S71-6. PubMed ID: 16858944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.